title: Posttreatment evaluation of central nervous system gliomas.
abstract: Although conventional contrast-enhanced MR imaging remains the standard-of-care imaging method in the posttreatment evaluation of gliomas, recent developments in therapeutic options such as chemoradiation and antiangiogenic agents have caused the neuro-oncology community to rethink traditional imaging criteria. This article highlights the latest recommendations. These recommendations should be viewed as works in progress. As more is learned about the pathophysiology of glioma treatment response, quantitative imaging biomarkers will be validated within this context. There will likely be further refinements to glioma response criteria, although the lack of technical standardization in image acquisition, postprocessing, and interpretation also need to be addressed.
authors: Division of Neuroradiology, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. mark.shiroishi@med.usc.edu
authors: Mark S
authors: MS
authors: Shiroishi
authors: Michael T
authors: MT
authors: Booker
authors: Manyoo
authors: M
authors: Agarwal
authors: Nidhi
authors: N
authors: Jain
authors: Ilana
authors: I
authors: Naghi
authors: Alexander
authors: A
authors: Lerner
authors: Meng
authors: M
authors: Law
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology* / Q000628:therapy*; D003287:Contrast Media; D005910:Glioma / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000592:standards*; D008495:Medical Oncology / Q000592:standards; D017063:Outcome Assessment, Health Care / Q000592:standards*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media